What is HCW Biologics Inc. (HCWB) stock price today?

HCW Biologics Inc. (HCWB) is currently trading at $1.55, up 1.31% today.

What is HCWB P/E ratio?

HCW Biologics Inc.'s P/E ratio is -0.03. This is below the market average, suggesting the stock may be undervalued relative to earnings.

What is HCWB return on equity (ROE)?

HCW Biologics Inc.'s return on equity (ROE) is -142.16%, indicating how efficiently the company generates profit from shareholders' equity. This is below the typical market average of 12-15%.

What is HCW Biologics Inc.'s market cap?

HCW Biologics Inc. has a market capitalization of $538844.

NASDAQ · Biotechnology

HCW Biologics Inc. (HCWB) Stock

$1.55 +1.31% NASDAQ: HCWB Healthcare

Valuation

Metric	Value
Price	$1.55
Market Cap	$538844
P/E Ratio	-0.03
P/B Ratio	0.08
P/S Ratio	0.09
EPS (TTM)	$-10.63
52-Week High	$29.28
52-Week Low	$1.50
Dividend Yield	0.00%

Financials & Margins

Metric	Value
ROE	-142.16%
ROA	-18.39%
ROCE	-75.79%
Gross Margin	99.24%
Operating Margin	-97.88%
Net Margin	-73.22%
Debt/Equity	0.88
Current Ratio	0.10

Annual Financials (USD)

Metric	2021	2022	2023	2024	2025
Revenue	$0	$7.0M	$3.0M	$3.0M	$0
Operating Profit	$-13.0M	$-15.0M	$-26.0M	$-29.0M	$-11.0M
Net Profit	$-13.0M	$-15.0M	$-25.0M	$-30.0M	$-8.0M
EPS	$-2.16	$-2.52	$-4.20	$-4.62	$-63.78
Op Margin	—	-224.3%	-905.0%	-1148.5%	-20757.7%

Balance Sheet (USD)

Metric	2021	2022	2023	2024	2025
Total Assets	$54.0M	$47.0M	$29.0M	$30.0M	$25.0M
Total Liabilities	$2.0M	$9.0M	$15.0M	$37.0M	$22.0M
Cash	$12.0M	$22.0M	$4.0M	$5.0M	$2.0M
Borrowings	$0	$6.0M	$6.0M	$14.0M	$7.0M

Latest News

HCW Biologics to Implement 1-for-6 Reverse Stock Split MT Newswires · Jun 30, 2026 HCW Biologics Regained Compliance with Bid Price Rule Per Nasdaq Compliance Letter GlobeNewswire · Jun 30, 2026 HCW Biologics Board Approves 1-for-6 Reverse Stock Split MT Newswires · Jun 26, 2026 HCW Biologics Announces 1-for-6 Reverse Stock Split Effective on June 30, 2026 GlobeNewswire · Jun 26, 2026 HCW Biologics Announces Positive Results for Preliminary Human Data Readout for Phase 1 Clinical Trial Evaluating IL-2 Based Fusion Immunotherapeutic, HCW9302 Monotherapy, in Alopecia Areata GlobeNewswire · Jun 16, 2026

Cash Flow (USD)

Metric	2021	2022	2023	2024	2025
Operating Cash Flow	$-11.0M	$-10.0M	$-23.0M	$-14.0M	$-13.0M
Investing Cash Flow	$-35.0M	$4.0M	$-2.0M	$-1.0M	$0
Financing Cash Flow	$-7.0M	$0	$0	$2.0M	$-1.0M
Net Cash Flow	$3.0M	$11.0M	$-19.0M	$1.0M	$-3.0M
Free Cash Flow	$-11.0M	$-21.0M	$-29.0M	$-14.0M	$-13.0M

Valuation & Return Ratios

Metric	Value
PEG Ratio	0.00
EV / EBITDA	-1.50
FCF Yield	-2078.09%
Quick Ratio	0.06
Interest Coverage	-17.08
Return 1Y	-83.56%
Return 3Y	-99.15%
Return 5Y	—

Ownership

Insiders Held9.24%

Institutions Held8.59%

Institutions Float Held9.47%

Institutional Holder	Shares	Report Date
HRT Financial LP	44,399	2026-03-31
Virtu Financial LLC	7,968	2026-03-31
Geode Capital Management, LLC	5,981	2026-03-31
Citadel Advisors Llc	4,347	2026-03-31
Tower Research Capital LLC (TRC)	2,474	2026-03-31

Peer Comparison

Ticker	Price	Change	P/E	Market Cap	Div Yield
ACXPAcurx Pharmaceuticals, Inc.	$1.27	+1.60%	-0.36	$5.46M	0.00%
ADILAdial Pharmaceuticals, Inc	$4.00	+0.76%	-0.26	$10.50M	0.00%
APREAprea Therapeutics, Inc.	$0.58	+4.73%	-0.64	$7.24M	0.00%
APVOAptevo Therapeutics Inc.	$1.81	+0.56%	-0.01	$3.96M	0.00%
BCDABioCardia, Inc.	$1.07	+0.94%	-1.54	$15.93M	0.00%

About HCW Biologics Inc.

HCW Biologics Inc. is led by CEO Hing C. Wong, employs 36 people, headquartered in US, publicly traded since 2021.

HCW Biologics Inc. (HCWB) stock trades at $1.55 with a market capitalization of $538844. The stock is valued at a price-to-earnings (P/E) ratio of -0.03, price-to-book of 0.08, price-to-sales of 0.09. Over the past 52 weeks the stock has ranged between $1.50 and $29.28, and currently trades 94.7% below its 52-week high.

On profitability, HCW Biologics Inc. generates a return on equity (ROE) of -142.16%, return on capital employed of -75.79%, an operating margin of -97.88%, a net profit margin of -73.22%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1172.83 +0.28% JNJ Johnson & Johnson $260.45 +1.55% ABBV AbbVie Inc. $276.98 +1.67% MRK Merck & Company, Inc. Common Stock (new) $145.34 +2.08% UNH UnitedHealth Group Incorporated Common Stock (DE) $376.24 +1.43% NVS Novartis AG $143.67 +0.39% AZN AstraZeneca PLC $159.80 +0.64% TMO Thermo Fisher Scientific Inc $658.31 +0.97% AMGN Amgen Inc. $413.31 +1.44% GILD Gilead Sciences, Inc. $150.80 +2.52% ABT Abbott Laboratories $99.69 +1.21% NVO Novo Nordisk A/S $38.39 +0.54%

Screens featuring this stock

High ROE Healthcare Stocks Low P/E Healthcare Stocks High Net Margin Healthcare Stocks Dividend Healthcare Stocks Low Debt Healthcare Stocks Nasdaq High ROE Stocks All stock screens

Run Stock Screener Investing Guides